HK1108312A1 - Medical use and composition for the treatment of lipid and glucose metabolism disorders - Google Patents

Medical use and composition for the treatment of lipid and glucose metabolism disorders

Info

Publication number
HK1108312A1
HK1108312A1 HK07110914.5A HK07110914A HK1108312A1 HK 1108312 A1 HK1108312 A1 HK 1108312A1 HK 07110914 A HK07110914 A HK 07110914A HK 1108312 A1 HK1108312 A1 HK 1108312A1
Authority
HK
Hong Kong
Prior art keywords
lipid
treatment
agonist
glucose metabolism
composition
Prior art date
Application number
HK07110914.5A
Other languages
English (en)
Inventor
Anthony H Cincotta
Original Assignee
Veroscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veroscience Llc filed Critical Veroscience Llc
Publication of HK1108312A1 publication Critical patent/HK1108312A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
HK07110914.5A 1996-05-07 2007-10-09 Medical use and composition for the treatment of lipid and glucose metabolism disorders HK1108312A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1737796P 1996-05-07 1996-05-07
US1933696P 1996-06-06 1996-06-06

Publications (1)

Publication Number Publication Date
HK1108312A1 true HK1108312A1 (en) 2008-05-02

Family

ID=26689794

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07110914.5A HK1108312A1 (en) 1996-05-07 2007-10-09 Medical use and composition for the treatment of lipid and glucose metabolism disorders

Country Status (9)

Country Link
EP (2) EP1776955B1 (xx)
AT (1) ATE344668T1 (xx)
CA (1) CA2254116C (xx)
DE (1) DE69736928T2 (xx)
DK (1) DK0934069T3 (xx)
ES (2) ES2277357T3 (xx)
HK (1) HK1108312A1 (xx)
PT (1) PT934069E (xx)
WO (1) WO1997041873A1 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6366298B1 (en) 1999-06-03 2002-04-02 Netzero, Inc. Monitoring of individual internet usage
US9655865B2 (en) * 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040077679A1 (en) * 2002-07-29 2004-04-22 Cincotta Anthony H. Therapeutic treatment for the metabolic syndrome and type 2 diabetes
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
EP1870096A3 (en) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
EP2316456B1 (en) 2003-04-29 2017-06-14 Orexigen Therapeutics, Inc. Compositions for affecting weight loss comprising an opioid antagonist and bupropion
EP1951212A2 (en) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20090090316A (ko) 2006-11-09 2009-08-25 오렉시젠 세러퓨틱스 인크. 체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법
AU2013263800B2 (en) * 2007-03-30 2016-05-05 Veroscience Llc Methods of treating metabolic syndrome using dopamine receptor agonists
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
WO2009062113A1 (en) * 2007-11-07 2009-05-14 Burnham Institute For Medical Research Method and compounds for modulating insulin production
AU2015201255B2 (en) * 2008-01-14 2016-05-19 Veroscience, Llc Parenteral formulations of dopamine agonists
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
EP4104824A1 (en) 2012-06-06 2022-12-21 Nalpropion Pharmaceuticals LLC Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3419293A (en) * 1991-12-23 1993-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College, The A therapeutic process for the treatment of the pathologies of type II diabetes

Also Published As

Publication number Publication date
DE69736928T2 (de) 2007-06-28
EP0934069A1 (en) 1999-08-11
EP0934069B1 (en) 2006-11-08
CA2254116C (en) 2009-10-20
EP1776955B1 (en) 2012-08-15
EP1776955A1 (en) 2007-04-25
ES2393303T3 (es) 2012-12-20
DE69736928D1 (de) 2006-12-21
DK0934069T3 (da) 2007-03-19
WO1997041873A1 (en) 1997-11-13
CA2254116A1 (en) 1997-11-13
PT934069E (pt) 2007-02-28
EP0934069A4 (en) 2002-12-04
ATE344668T1 (de) 2006-11-15
ES2277357T3 (es) 2007-07-01

Similar Documents

Publication Publication Date Title
HK1108312A1 (en) Medical use and composition for the treatment of lipid and glucose metabolism disorders
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
MY116478A (en) Tri-substituted imidazoles having multiple therapeutic properties
MX9700030A (es) Administracion de pirenzipina, matilescopolamina y otros antagonistas del receptor mascurinico para el tratamiento de transtornos del metabolismo de lipidos.
DE69531457D1 (en) Sulfonamide
GR3021804T3 (en) Indole derivatives as 5-h1-like agonists for use in migraine
PT1235787E (pt) Receptores agonistas beta2 adrenergicos
GEP20032958B (en) Adenosine Derivatives
BG106104A (en) Method for the treatment of diseases related to increased number of neutrophils or neutrophil overactivation
GR3030371T3 (en) Triazole compounds and their use as dopamine-d 3?-ligands
IL110943A0 (en) Compositions for the treatment of skin disorders
SE9803760D0 (sv) Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
BG105539A (en) Eletriptan hydrobromide monohydrate
HUT73231A (en) Pharmaceutical compositions with 17-beta-monosubstituted-carbamoyl-4-aza-5-alpha-androst-1-en-3-ones for treatment of chronic prostatitis
MY142646A (en) Chemokine receptor antagonists and methods of use therefor
DE59308900D1 (de) (-)-metrifonat enthaltendes arzneimittel
NZ336362A (en) Use of a 15-keto-prostaglandin compound as a portal hypertension inhibitor
MY108739A (en) Imidazole, triazole and tetrazole derivatives
MY128351A (en) ß2-ADRENERGIC RECEPTOR AGONISTS
ATE346615T1 (de) Mittel zur verbesserung der gewebepenetration
ZA962946B (en) Anellated beta-carbolines
MX9709684A (es) Uso de derivados de vitamina d4 para tratamiento de trastornos de la piel.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160506